Cerevance Announces Positive Phase 3 ARISE Results: Once-daily Oral Solengepras Meets Primary Endpoint and Demonstrates Motor and Non-motor Benefits in Parkinson's Disease
Phase 3positiveSolengeprasPositive
AI Analysis
Summary
Cerevance announced on October 7, 2026 positive topline results from its Phase 3 ARISE trial, in which once-daily oral solengepras met its primary endpoint. The drug also showed motor and non-motor benefits in Parkinson's disease.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Met
Outcome Details
Phase 3 ARISE trial of once-daily oral solengepras met its primary endpoint and demonstrated motor and non-motor benefits in Parkinson's disease.
Importance:8/10
Sentiment:
0.85
Parkinson's diseasePhase 3topline resultsneurodegenerationoral therapyprivate company
Read the original article
Published by Drugs.com Clinical Trial Results on October 7, 2026 9:10 PM